Pharmaceutical

ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy

The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.

Sep 6, 2024 - 04:00
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.
Read the original article

Tags:

Previous Article

ESC 2024: Insights into RNA as therapeutic target and tool

Next Article

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Genentech buys Regor’s CDK inhibitors in $850m deal 

Genentech buys Regor’s CDK inhibitors in $850m deal 

Oct 2, 2024

FDA calls for treatments for meth and cocaine addiction

FDA calls for treatments for meth and cocaine addiction

Oct 4, 2023

Opinion: STAT+: Why we created a chatbot to help people at risk for eating disorders

Opinion: STAT+: Why we created a chatbot to help people...

Jun 12, 2023